Table 3 Univariate and multivariate analyses for progression-free survival after bevacizumab administration in all cases included in this study
Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
Variables | Hazard ratio (95% CI) | p-Value | Hazard ratio (95% CI) | p-Value | |
Method of bevacizumab administration | Group A vs. group B | 0.47 (0.27–0.80) | < 0.01 | 0.53 (0.29–0.95) | 0.03 |
Age (years) | ≥ 50 vs. < 50 | 1.83 (1.01–3.50) | 0.045 | 1.40 (0.73–2.81) | 0.31 |
Drug combined with bevacizumab | Gemcitabine vs. other regimens | 1.70 (0.95–3.25) | 0.08 | ||
Histology | Serous carcinoma vs. other histology | 0.73 (0.43–1.24) | 0.24 | ||
Residual tumor at primary surgery | < 1 cm vs. ≥ 1 cm | 0.94 (0.55–1.58) | 0.82 | ||
FIGO stage | I, II vs. III, IV | 0.98 (0.54–1.90) | 0.95 | ||